{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:09:56Z","timestamp":1785434996017,"version":"3.56.0"},"reference-count":81,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2017.00357","type":"journal-article","created":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T03:57:22Z","timestamp":1496980642000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Evaluation of JNJ-54717793 a Novel Brain Penetrant Selective Orexin 1 Receptor Antagonist in Two Rat Models of Panic Attack Provocation"],"prefix":"10.3389","volume":"8","author":[{"given":"Pascal","family":"Bonaventure","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Dugovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brock","family":"Shireman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Preville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujin","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Nepomuceno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Wennerholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Lovenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Carruthers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie D.","family":"Fitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anantha","family":"Shekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/0028-3908(88)90013-5","article-title":"Injection of L-allylglycine into the posterior hypothalamus in rats causes decreases in local GABA which correlate with increases in heart rate.","volume":"27","author":"Abshire","year":"1988","journal-title":"Neuropharmacology"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0022-3565(25)23211-6","article-title":"Effect of local inhibition of gamma-aminobutyric acid uptake in the dorsomedial hypothalamus on extracellular levels of gamma-aminobutyric acid and on stress-induced tachycardia: a study using microdialysis.","volume":"255","author":"Anderson","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1177\/0269881105059253","article-title":"Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.","volume":"19","author":"Baldwin","year":"2005","journal-title":"J. Psychopharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1001\/archpsyc.1988.01800290027004","article-title":"Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment.","volume":"45","author":"Ballenger","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/15622970802465807","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.","volume":"9","author":"Bandelow","year":"2008","journal-title":"World J. Biol. Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1046\/j.0953-816x.2001.01777.x","article-title":"Orexins (hypocretins) directly excite tuberomammillary neurons.","volume":"14","author":"Bayer","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.neuropharm.2014.09.012","article-title":"Both Ox1r and Ox2r orexin receptors contribute to the cardiovascular and locomotor components of the novelty stress response in the rat.","volume":"89","author":"Beig","year":"","journal-title":"Neuropharmacology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/1440-1681.12461","article-title":"Both Ox1R and Ox2R orexin receptors contribute to the cardiorespiratory response evoked from the perifornical hypothalamus.","volume":"42","author":"Beig","year":"","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1124\/jpet.115.225466","article-title":"Characterization of JNJ-42847922, a selective orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia.","volume":"354","author":"Bonaventure","year":"","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1124\/jpet.114.220392","article-title":"A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects.","volume":"352","author":"Bonaventure","year":"","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7266","article-title":"Antagonistic interplay between hypocretin and leptin in the lateral hypothalamus regulates stress responses.","volume":"6","author":"Bonnavion","year":"2015","journal-title":"Nat. Commun."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1016\/j.bmcl.2015.05.012","article-title":"Recent trends in orexin research\u20132010 to 2015.","volume":"25","author":"Boss","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1001\/archpsyc.1985.01790280055005","article-title":"Noradrenergic function and the mechanism of action of antianxiety treatment. II. The effect of long-term imipramine treatment.","volume":"42","author":"Charney","year":"1985","journal-title":"Arch. Gen. Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/YCO.0b013e32831a473d","article-title":"Current use of benzodiazepines in anxiety disorders.","volume":"22","author":"Cloos","year":"2009","journal-title":"Curr. Opin. Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1600-0447.1994.tb01553.x","article-title":"Continuous monitoring of panic.","volume":"90","author":"de Beurs","year":"1994","journal-title":"Acta Psychiatr. Scand."},{"key":"B17","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/sleep\/27.5.851","article-title":"The diurnal rhythm of hypocretin in young and old F344 rats.","volume":"27","author":"Desarnaud","year":"2004","journal-title":"Sleep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.resp.2009.12.002","article-title":"The orexin receptor 1 (OX1R) in the rostral medullary raphe contributes to the hypercapnic chemoreflex in wakefulness, during the active period of the diurnal cycle.","volume":"170","author":"Dias","year":"2010","journal-title":"Respir. Physiol. Neurobiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1124\/jpet.109.152009","article-title":"Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat.","volume":"330","author":"Dugovic","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2014.00028","article-title":"Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism.","volume":"8","author":"Dugovic","year":"2014","journal-title":"Front. Neurosci."},{"key":"B21","doi-asserted-by":"crossref","first-page":"9273","DOI":"10.1523\/JNEUROSCI.21-23-09273.2001","article-title":"Orexin\/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus.","volume":"21","author":"Eriksson","year":"2001","journal-title":"J. Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.tins.2015.06.005","article-title":"Orexins and fear: implications for the treatment of anxiety disorders.","volume":"38","author":"Flores","year":"2015","journal-title":"Trends Neurosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1038\/npp.2014.146","article-title":"The hypocretin\/orexin system mediates the extinction of fear memories.","volume":"39","author":"Flores","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0005-7967(99)00074-1","article-title":"Evoking analogue subtypes of panic attacks in a nonclinical population using carbon dioxide-enriched air.","volume":"38","author":"Forsyth","year":"2000","journal-title":"Behav. Res. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1111\/j.1460-9568.2009.06952.x","article-title":"Hypocretin\/orexin contributes to the expression of some but not all forms of stress and arousal.","volume":"30","author":"Furlong","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/archpsyc.58.7.681","article-title":"Early coadministration of clonazepam with sertraline for panic disorder.","volume":"58","author":"Goddard","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1176\/ajp.151.4.547","article-title":"Anxiogenic effects of CO2 and hyperventilation in patients with panic disorder.","volume":"151","author":"Gorman","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/srep27147","article-title":"Orexin 2 receptor antagonism is sufficient to promote NREM and REM sleep from mouse to man.","volume":"6","author":"Gotter","year":"2016","journal-title":"Sci. Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1038\/npp.2013.109","article-title":"Differential effect of orexin-1 and CRF-1 antagonism on stress circuits: a fMRI study in the rat with the pharmacological stressor Yohimbine.","volume":"38","author":"Gozzi","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.physbeh.2013.10.005","article-title":"Optogenetic examination identifies a context-specific role for orexins\/hypocretins in anxiety-related behavior.","volume":"130","author":"Heydendael","year":"2013","journal-title":"Physiol. Behav."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ani6080045","article-title":"Evaluation of low versus high volume per minute displacement CO2 methods of euthanasia in the induction and duration of panic-associated behavior and physiology.","volume":"6","author":"Hickman","year":"2016","journal-title":"Animals"},{"key":"B32","doi-asserted-by":"publisher","first-page":"9965","DOI":"10.1073\/pnas.181330998","article-title":"Arousal effect of orexin A depends on activation of the histaminergic system.","volume":"98","author":"Huang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B33","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/da.22403","article-title":"Orexin 1 and 2 receptor involvement in CO2-induced panic-associated behavior and autonomic responses.","volume":"32","author":"Johnson","year":"2015","journal-title":"Depress. Anxiety"},{"key":"B34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/0269881112454230","article-title":"Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats.","volume":"27","author":"Johnson","year":"","journal-title":"J. Psychopharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/0269881109353464","article-title":"Induction of c-Fos in \u2019panic\/defence\u2019-related brain circuits following brief hypercarbic gas exposure.","volume":"25","author":"Johnson","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/0269881105053281","article-title":"Acute hypercarbic gas exposure reveals functionally distinct subpopulations of serotonergic neurons in rats.","volume":"19","author":"Johnson","year":"2005","journal-title":"J. Psychopharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/B978-0-444-59489-1.00009-4","article-title":"Orexin, stress, and anxiety\/panic states.","volume":"198","author":"Johnson","year":"","journal-title":"Prog. Brain Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.physbeh.2012.04.016","article-title":"Orexin 1 receptors are a novel target to modulate panic responses and the panic brain network.","volume":"107","author":"Johnson","year":"","journal-title":"Physiol. Behav."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/npp.2012.38","article-title":"Activation of the orexin 1 receptor is a critical component of CO2-mediated anxiety and hypertension but not bradycardia.","volume":"37","author":"Johnson","year":"","journal-title":"Neuropsychopharmacology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"7093","DOI":"10.1523\/JNEUROSCI.0408-06.2006","article-title":"Panic-prone state induced in rats with GABA dysfunction in the dorsomedial hypothalamus is mediated by NMDA receptors.","volume":"26","author":"Johnson","year":"2006","journal-title":"J. Neurosci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.physbeh.2012.03.016","article-title":"An animal model of panic vulnerability with chronic disinhibition of the dorsomedial\/perifornical hypothalamus.","volume":"107","author":"Johnson","year":"2012","journal-title":"Physiol. Behav."},{"key":"B42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nm.2075","article-title":"A key role for orexin in panic anxiety.","volume":"16","author":"Johnson","year":"2010","journal-title":"Nat. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1038\/sj.npp.1301621","article-title":"Neural pathways underlying lactate-induced panic.","volume":"33","author":"Johnson","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.autneu.2008.03.004","article-title":"Emotional and state-dependent modification of cardiorespiratory function: role of orexinergic neurons.","volume":"142","author":"Kuwaki","year":"2008","journal-title":"Auton. Neurosci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/sj.bjp.0705610","article-title":"Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor.","volume":"141","author":"Langmead","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/j.1476-5381.2009.00127.x","article-title":"Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX2 receptor.","volume":"156","author":"Malherbe","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.5665\/sleep.2232","article-title":"The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors.","volume":"35","author":"Mang","year":"2012","journal-title":"Sleep"},{"key":"B48","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/cne.1190","article-title":"Differential expression of orexin receptors 1 and 2 in the rat brain.","volume":"435","author":"Marcus","year":"2001","journal-title":"J. Comp. Neurol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","article-title":"The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.","volume":"59","author":"Mignot","year":"2002","journal-title":"Arch. Neurol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0006-8993(99)01336-0","article-title":"Distribution of orexin neurons in the adult rat brain.","volume":"827","author":"Nambu","year":"1999","journal-title":"Brain Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1017\/S1461145702003048","article-title":"Generalized anxiety disorder: comorbidity, comparative biology and treatment.","volume":"5","author":"Nutt","year":"2002","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B52","author":"Paxinos","year":"2005","journal-title":"The Rat Brain in Stereotaxic Coordinates."},{"key":"B53","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","article-title":"Neurons containing hypocretin (orexin) project to multiple neuronal systems.","volume":"18","author":"Peyron","year":"1998","journal-title":"J. Neurosci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJM196712212772502","article-title":"Lactate metabolism in anxiety neurosis.","volume":"277","author":"Pitts","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"B55","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-007-0821-0","article-title":"A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder.","volume":"194","author":"Pollack","year":"","journal-title":"Psychopharmacology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/da.20218","article-title":"A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.","volume":"24","author":"Pollack","year":"","journal-title":"Depress. Anxiety"},{"key":"B57","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00482-005-0462-3","article-title":"Deep brain stimulation in the posterior hypothalamus for chronic cluster headache. Case report and review of the literature.","volume":"20","author":"Rasche","year":"2006","journal-title":"Schmerz"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.137","article-title":"A role for the extended amygdala in the fear-enhancing effects of acute selective serotonin reuptake inhibitor treatment.","volume":"3","author":"Ravinder","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"B59","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1113\/jphysiol.2001.013302","article-title":"Tachycardia evoked by disinhibition of the dorsomedial hypothalamus in rats is mediated through medullary raphe.","author":"Samuels","year":"2002","journal-title":"J. Physiol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0091-3057(95)00153-N","article-title":"Regulation of anxiety by GABAA receptors in the rat amygdala.","volume":"52","author":"Sanders","year":"1995","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B61","doi-asserted-by":"publisher","first-page":"20260","DOI":"10.1073\/pnas.1320325110","article-title":"Orexin\/hypocretin system modulates amygdala-dependent threat learning through the locus coeruleus.","volume":"110","author":"Sears","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B62","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0028-3908(87)90020-7","article-title":"Defense reaction elicited by injection of GABA antagonists and synthesis inhibitors into the posterior hypothalamus in rats.","volume":"26","author":"Shekhar","year":"1987","journal-title":"Neuropharmacology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0006-8993(90)91173-E","article-title":"GABA receptors in the posterior hypothalamus regulate experimental anxiety in rats.","volume":"512","author":"Shekhar","year":"1990","journal-title":"Brain Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1017\/S1461145710001355","article-title":"A selective, non-peptide CRF receptor 1 antagonist prevents sodium lactate-induced acute panic-like responses.","volume":"14","author":"Shekhar","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"9205","DOI":"10.1523\/JNEUROSCI.2491-06.2006","article-title":"Angiotensin-II is a putative neurotransmitter in lactate-induced panic-like responses in rats with disruption of GABAergic inhibition in the dorsomedial hypothalamus.","volume":"26","author":"Shekhar","year":"2006","journal-title":"J. Neurosci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/0091-3057(94)00307-5","article-title":"Dorsomedial hypothalamic GABA regulates anxiety in the social interaction test.","volume":"50","author":"Shekhar","year":"1995","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B67","doi-asserted-by":"crossref","first-page":"9726","DOI":"10.1523\/JNEUROSCI.17-24-09726.1997","article-title":"The circumventricular organs form a potential neural pathway for lactate sensitivity: implications for panic disorder.","volume":"17","author":"Shekhar","year":"1997","journal-title":"J. Neurosci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0091-3057(96)00077-9","article-title":"Dorsomedial hypothalamic GABA dysfunction produces physiological arousal following sodium lactate infusions.","volume":"55","author":"Shekhar","year":"1996","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B69","first-page":"R689","article-title":"Hypothalamic excitatory amino acid receptors mediate stress-induced tachycardia in rats.","author":"Soltis","year":"1992","journal-title":"Am. J. Physiol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00213-012-2736-7","article-title":"The brain orexin system and almorexant in fear-conditioned startle reactions in the rat.","volume":"223","author":"Steiner","year":"2012","journal-title":"Psychopharmacology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/cmdc.201300003","article-title":"Discovery and characterization of ACT-335827 an orally available, brain penetrant orexin receptor type 1 selective antagonist.","volume":"8","author":"Steiner","year":"2013","journal-title":"ChemMedChem"},{"key":"B72","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.brainres.2005.03.002","article-title":"Orexin-A (hypocretin-1) is possibly involved in generation of anxiety-like behavior.","volume":"1044","author":"Suzuki","year":"2005","journal-title":"Brain Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/00005053-198608000-00006","article-title":"Successful use of clonazepam in patients with treatment-resistant panic disorder.","volume":"174","author":"Tesar","year":"1986","journal-title":"J. Nerv. Ment. Dis."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/brain\/awm097","article-title":"Hypocretin (orexin) cell loss in Parkinson\u2019s disease.","author":"Thannickal","year":"2007","journal-title":"Brain"},{"key":"B75","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0014-5793(98)01266-6","article-title":"Distribution of orexin receptor mRNA in the rat brain.","volume":"438","author":"Trivedi","year":"1998","journal-title":"FEBS Lett."},{"key":"B76","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bbr.2016.08.052","article-title":"Role of the orexin (hypocretin) system in contextual fear conditioning in rats.","volume":"316","author":"Wang","year":"2017","journal-title":"Behav. Brain Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3171\/2011.3.JNS101574","article-title":"Mapping of microstimulation evoked responses and unit activity patterns in the lateral hypothalamic area recorded in awake humans. Technical note.","volume":"115","author":"Wilent","year":"2011","journal-title":"J. Neurosurg."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3171\/2009.9.JNS09577","article-title":"Induction of panic attack by stimulation of the ventromedial hypothalamus.","volume":"112","author":"Wilent","year":"2010","journal-title":"J. Neurosurg."},{"key":"B79","doi-asserted-by":"publisher","first-page":"10685","DOI":"10.1073\/pnas.0702676104","article-title":"Control of hypothalamic orexin neurons by acid and CO2.","volume":"104","author":"Williams","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B80","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/archpsyc.1988.01800250051007","article-title":"Carbon dioxide-induced anxiety. Behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects.","volume":"45","author":"Woods","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2014.00036","article-title":"Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls.","volume":"8","author":"Yeoh","year":"2014","journal-title":"Front. Neurosci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00357\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T02:25:50Z","timestamp":1750299950000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00357\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,9]]},"references-count":81,"alternative-id":["10.3389\/fphar.2017.00357"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2017.00357","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,9]]},"article-number":"357"}}